Tanespimycin (17-AAG)

製品コードS1141 別名：CP127374,NSC-330507, KOS 953

分子量(MW)：585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

サイズ

価格(税別)

10mM (in 1mL DMSO)	JPY 32370.00
25mg	JPY 24900.00
100mg	JPY 61420.00

お問い合わせバルク問合せ

具体的な在庫状況を確認してください。電話番号:06 6398 9525 | 電子メール：[email protected]

文献中Selleckの製品使用例(20)

カスタマーフィードバック(9)

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明

特性

Displays very low toxicity toward normal cells.

ターゲット

HSP90 ^[1]
(Cell-free assay)

5 nM

体外試験

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
A549	M1LHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\sd4Z3UUN3ME2wMlAxODNyMzFOwG0>	NULUToJjW0GQR1XS
IST-MEL1	NYnVOGt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH0[o1pUUN3ME2wMlAxODRyNzFOwG0>	MlfNV2FPT0WU
NCI-SNU-1	NHW4fodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvnWlFKSzVyPUCuNFAzODdizszN	MUPTRW5ITVJ?
FADU	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PxdmlEPTB;MD6wNFIxQSEQvF2=	MnvMV2FPT0WU
C32	NYfFeVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfCfnpCUUN3ME2wMlAxOzB2IN88US=>	NEHNZWJUSU6JRWK=
D-566MG	NV7Z[YZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrOT21KSzVyPUCuNFA{QSEQvF2=	MULTRW5ITVJ?
LXF-289	NXnGUnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DTTmlEPTB;MD6wNFQyQSEQvF2=	NES1eYlUSU6JRWK=
HGC-27	NF3DZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rBVWlEPTB;MD6wNFUyKM7:TR?=	MWjTRW5ITVJ?
RPMI-7951	NUDjeVVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXjNldKSzVyPUCuNFA4OTdizszN	NVX1dGp3W0GQR1XS
HSC-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPsNoNmUUN3ME2wMlAxQTJ7IN88US=>	Mlz6V2FPT0WU
MIA-PaCa-2	NIftOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFGxUolKSzVyPUCuNFExODlizszN	MWXTRW5ITVJ?
KS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XqeWlEPTB;MD6wNVM2PSEQvF2=	NIrsfVNUSU6JRWK=
CAL-51	NXHLeWxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fIfGlEPTB;MD6wNVQxPSEQvF2=	M4LwW3NCVkeHUh?=
MDA-MB-361	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHFNGZKSzVyPUCuNFE1QTVizszN	NWjBTpBwW0GQR1XS
TI-73	NVL6b25RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPMTWM2OD1yLkCxO\|k3KM7:TR?=	M{TjS3NCVkeHUh?=
AGS	M3q4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHmTWM2OD1yLkCxPVM5KM7:TR?=	NVLITlJ[W0GQR1XS
NCI-H460	M2e0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rWV2lEPTB;MD6wNVk4PCEQvF2=	MkG3V2FPT0WU
A204	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEKyOFkh\|ryP	M1r0cnNCVkeHUh?=
CHL-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTjNWNZUUN3ME2wMlAzOjVzIN88US=>	MljVV2FPT0WU
DU-4475	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17UPWlEPTB;MD6wNlI3OSEQvF2=	Ml\zV2FPT0WU
CGTH-W-1	NVH3NWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PG[mlEPTB;MD6wNlM1QSEQvF2=	MU\TRW5ITVJ?
HCC2218	M4fOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XJSmlEPTB;MD6wNlQ6PCEQvF2=	NXzw[IhmW0GQR1XS
A2780	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE[4b\|FKSzVyPUCuNFI2OzFizszN	M37Md3NCVkeHUh?=
NCI-H720	NEHOc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TmfWlEPTB;MD6wNlU1PiEQvF2=	NVrw[nlvW0GQR1XS
NCI-N87	NYL5ZYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEK1PVMh\|ryP	NX\GdIMyW0GQR1XS
CHP-212	NYO4eo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjafFl1UUN3ME2wMlAzPjJ6IN88US=>	NGrveIRUSU6JRWK=
NCI-H23	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmG3TWM2OD1yLkCyOlY2KM7:TR?=	NXnDWWd5W0GQR1XS
D-263MG	NYHDV\|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMEK3PFYh\|ryP	M1\Hd3NCVkeHUh?=
ME-180	M3fCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEK4PVEh\|ryP	Mni3V2FPT0WU
SW982	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMEK5PVkh\|ryP	M4H0WnNCVkeHUh?=
OE19	M4[0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEOwO\|ch\|ryP	MWrTRW5ITVJ?
SK-LU-1	NH;kN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i2Z2lEPTB;MD6wN\|A5OiEQvF2=	MUTTRW5ITVJ?
H4	NFnyNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjLTWM2OD1yLkCzNFkh\|ryP	MXfTRW5ITVJ?
HT-144	NEixb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTYWJlQUUN3ME2wMlA{ODl\|IN88US=>	MYXTRW5ITVJ?
SK-UT-1	NI[xNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMEOxO\|gh\|ryP	MUHTRW5ITVJ?
D-336MG	M2nmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\nXGlEPTB;MD6wN\|MxQSEQvF2=	NF3Tb4tUSU6JRWK=
MDA-MB-175-VII	NGL3XXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX0ZmlKSzVyPUCuNFM{PTRizszN	MVPTRW5ITVJ?
GAMG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEO0N\|Uh\|ryP	NIniT\|RUSU6JRWK=
CP50-MEL-B	NXS4[4V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fCeWlEPTB;MD6wN\|Q2KM7:TR?=	NEDSTlNUSU6JRWK=
OVCAR-5	M13NVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDPc\|FKSzVyPUCuNFM1QCEQvF2=	M3S4RXNCVkeHUh?=
SK-MES-1	NYqzNpV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\LVJhFUUN3ME2wMlA{PjB4IN88US=>	MVvTRW5ITVJ?
VM-CUB-1	MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nnS2lEPTB;MD6wN\|Y2PyEQvF2=	MV7TRW5ITVJ?
WM-115	NUPhUXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvZTWM2OD1yLkCzO\|YzKM7:TR?=	NXPMUIEzW0GQR1XS
DSH1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLBTWM2OD1yLkCzPFA4KM7:TR?=	NWPnS\|RYW0GQR1XS
Becker	M1LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEO4PFUh\|ryP	NVnKWo5{W0GQR1XS
SW962	NEHDN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\QZY8{UUN3ME2wMlA{QTR3IN88US=>	NF\SPXZUSU6JRWK=
TYK-nu	NGXhdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzqW4RKSzVyPUCuNFM6QDVizszN	NWXF[4tCW0GQR1XS
HO-1-N-1	NVS2bXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPJN4ZKSzVyPUCuNFQxOjFizszN	MYnTRW5ITVJ?
T98G	NXf0dodCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Twb2lEPTB;MD6wOFExOyEQvF2=	MofOV2FPT0WU
ACN	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMESxOlIh\|ryP	MVLTRW5ITVJ?
SW780	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3zW3pKSzVyPUCuNFQzODNizszN	NXrmOFFTW0GQR1XS
Detroit562	NX;nS4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYT2VXoyUUN3ME2wMlA1OjN7IN88US=>	NYXUboNEW0GQR1XS
BB49-HNC	NX7a[2Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnO[4NFUUN3ME2wMlA1OjR\|IN88US=>	M1LwN3NCVkeHUh?=
HN	Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\JTWM2OD1yLkC0NlczKM7:TR?=	MlHuV2FPT0WU
H9	M2PTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvVeVJKSzVyPUCuNFQ{PzFizszN	MXrTRW5ITVJ?
VA-ES-BJ	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXwTWM2OD1yLkC0OFQ4KM7:TR?=	NEXZZWNUSU6JRWK=
MEL-JUSO	NX\RVJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz5bmNUUUN3ME2wMlA1PDd3IN88US=>	MVjTRW5ITVJ?
BT-474	NWDubpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkmwTWM2OD1yLkC0OUDPxE1?	MX;TRW5ITVJ?
CaR-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMES1OFkh\|ryP	NUTRfYdoW0GQR1XS
PSN1	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;ZSWlEPTB;MD6wOFYxOyEQvF2=	M3vDPXNCVkeHUh?=
KYSE-510	NEXCZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPzOJA1UUN3ME2wMlA1PjR7IN88US=>	NUXGNWVMW0GQR1XS
KP-4	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMES3OVMh\|ryP	NHj4SlZUSU6JRWK=
KYSE-410	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV64eJBCUUN3ME2wMlA1Pzd{IN88US=>	NVzMZmZHW0GQR1XS
G-402	NHTMTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMES3PFkh\|ryP	M1\j[HNCVkeHUh?=
DOK	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInIUoZKSzVyPUCuNFQ6ODJizszN	M2\pZXNCVkeHUh?=
COR-L88	NWLZXIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fVR2lEPTB;MD6wOFkyOiEQvF2=	NU\MNJJTW0GQR1XS
SKG-IIIa	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPHTWM2OD1yLkC0PVg3KM7:TR?=	NXG4NnQxW0GQR1XS
AN3-CA	M3u4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXHSYJ6UUN3ME2wMlA2KM7:TR?=	NUjsZpNIW0GQR1XS
SW48	NH6xWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHpcnVKSzVyPUCuNFUxOzlizszN	M2fPZnNCVkeHUh?=
YKG-1	M3;Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLpOm1SUUN3ME2wMlA2ODdzIN88US=>	MnjVV2FPT0WU
KYSE-150	M{GyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXuNHB4UUN3ME2wMlA2OjN3IN88US=>	MXHTRW5ITVJ?
HuO-3N1	NH:1d5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\iTWM2OD1yLkC1NlM4KM7:TR?=	NFPXR5RUSU6JRWK=
LB1047-RCC	NVfmWGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMEWyPVYh\|ryP	MVPTRW5ITVJ?
NCI-H2030	NIPq[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG3TWM2OD1yLkC1OFE1KM7:TR?=	MXXTRW5ITVJ?
YH-13	NYjmbHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEW3NlIh\|ryP	NYewfpBWW0GQR1XS
5637	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:3S5ZKSzVyPUCuNFU4PCEQvF2=	M4PKcHNCVkeHUh?=
LOXIMVI	NWPhNYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;uWFh[UUN3ME2wMlA2QDd{IN88US=>	MXLTRW5ITVJ?
GT3TKB	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\RboI4UUN3ME2wMlA2QTR{IN88US=>	NECyT5FUSU6JRWK=
TCCSUP	M{XKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\mTWM2OD1yLkC1PVY1KM7:TR?=	NXf1O5pFW0GQR1XS
EPLC-272H	M1TMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3e5WGlEPTB;MD6wOlIxPSEQvF2=	Mlf5V2FPT0WU
LU-99A	NV3YSnd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHmXlZJUUN3ME2wMlA3OjN5IN88US=>	MoTRV2FPT0WU
NCI-H1755	NEn0c2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHtOFhKSzVyPUCuNFY{PDFizszN	NYLRN\|EyW0GQR1XS
KM12	NWfJVo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwME[zOFgh\|ryP	MonEV2FPT0WU
SF295	NH3mTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTWTWM2OD1yLkC2OFUzKM7:TR?=	NFfkelRUSU6JRWK=
MZ2-MEL	NH\hdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwME[1OVMh\|ryP	Ml\rV2FPT0WU
HEC-1	NH\0O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwME[1PFgh\|ryP	M1u0dnNCVkeHUh?=
SW684	NF\GfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwME[1PVEh\|ryP	M1vPbXNCVkeHUh?=
SF539	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\Xco5KSzVyPUCuNFY3QDFizszN	M3PubXNCVkeHUh?=
GMS-10	NV65bINlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj2TWM2OD1yLkC2Olk6KM7:TR?=	NEXvcJpUSU6JRWK=
MV-4-11	M2m5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXrOotKSzVyPUCuNFY5ODNizszN	NH\Tc5lUSU6JRWK=
HT-29	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwME[5NVkh\|ryP	M1XOOHNCVkeHUh?=
23132-87	M3\GOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwME[5OUDPxE1?	M2L3XHNCVkeHUh?=
SW620	NEHvcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\3U3FKSzVyPUCuNFcxOjZizszN	MnfhV2FPT0WU
HCC1806	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYS0PVhjUUN3ME2wMlA4OTNzIN88US=>	MUXTRW5ITVJ?
Hs-578-T	NF;iPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfifmZrUUN3ME2wMlA4OjB6IN88US=>	MYPTRW5ITVJ?
A2058	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvLV2JKSzVyPUCuNFczOjhizszN	NF;vem9USU6JRWK=
MEL-HO	NFPM[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEeyOVUh\|ryP	NFvvT\|ZUSU6JRWK=
HCC2998	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwMEezOFch\|ryP	NELZbmpUSU6JRWK=
HuO9	NUPnTnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEe1PFkh\|ryP	M2HDcHNCVkeHUh?=
CAL-39	NV32blhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDoT\|BKSzVyPUCuNFc4PjZizszN	M2HMeXNCVkeHUh?=
M14	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzaTWM2OD1yLkC3PVE{KM7:TR?=	NWX5OIFVW0GQR1XS
BFTC-909	NGHaOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEe5Olkh\|ryP	MlfnV2FPT0WU
TE-11	M2X6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XMR2lEPTB;MD6wO\|k6PiEQvF2=	MY\TRW5ITVJ?
TGBC1TKB	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3KT405UUN3ME2wMlA5ODR\|IN88US=>	NHLzPYhUSU6JRWK=
L-363	NGe3c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUO2TGU4UUN3ME2wMlA5OjB4IN88US=>	MVPTRW5ITVJ?
A431	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjzWoZKSzVyPUCuNFgzOSEQvF2=	NUi5bm94W0GQR1XS
MKN45	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHFTWM2OD1yLkC4NlE6KM7:TR?=	NH\Gb25USU6JRWK=
HT-1080	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[4XJhqUUN3ME2wMlA5PDN7IN88US=>	MYrTRW5ITVJ?
OVCAR-8	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnucpVKSzVyPUCuNFg3OjJizszN	NX7qUIp6W0GQR1XS
LCLC-97TM1	M17nOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NImwZ2ZKSzVyPUCuNFg4OjhizszN	MXLTRW5ITVJ?
M059J	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEmwNlch\|ryP	NVfmV5pSW0GQR1XS
SK-MEL-2	NXfzZYtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEmwOkDPxE1?	MmjZV2FPT0WU
TE-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEmyNFQh\|ryP	MmjhV2FPT0WU
KYSE-180	M4myO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMEmyOlIh\|ryP	MW\TRW5ITVJ?
D-247MG	NXHUVWN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMEm0OVUh\|ryP	M4LrTHNCVkeHUh?=
8-MG-BA	NFHr[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TPdmlEPTB;MD6wPVQ4OiEQvF2=	NH7OVG9USU6JRWK=
NCI-H1792	NULaS3hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\1SGlEPTB;MD6wPVYyQCEQvF2=	MULTRW5ITVJ?
MCF7	M1zNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTYNoxKSzVyPUCuNFk3PzdizszN	NH:zWlZUSU6JRWK=
NCI-H2122	NVrq[FdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXWTWM2OD1yLkC5O\|Q2KM7:TR?=	MXXTRW5ITVJ?
EFO-27	NHuzUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTkTWM2OD1yLkC5PVk4KM7:TR?=	NUnvbXNRW0GQR1XS
LB2241-RCC	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMUCwOVQh\|ryP	NYPremtpW0GQR1XS
SN12C	NYHzWohNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\rTYFKSzVyPUCuNVAyODdizszN	MonjV2FPT0WU
A498	NHjWXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoS0TWM2OD1yLkGwNVgh\|ryP	MlHkV2FPT0WU
PANC-03-27	NHHNbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vGNWlEPTB;MD6xNFI5PiEQvF2=	MojTV2FPT0WU
NCI-H1581	Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHm2T\|FKSzVyPUCuNVAzQSEQvF2=	NEnqOJZUSU6JRWK=
U-87-MG	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXvTWM2OD1yLkGwN\|A4KM7:TR?=	MXPTRW5ITVJ?
G-401	NHPZSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPoTWM2OD1yLkGwN\|U{KM7:TR?=	MWTTRW5ITVJ?
SiHa	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\ZTWM2OD1yLkGwOFg3KM7:TR?=	NHrYR\|hUSU6JRWK=
U251	NX;lfGNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3foVWlEPTB;MD6xNFUzPSEQvF2=	NHGyZnNUSU6JRWK=
MMAC-SF	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXoT4NKSzVyPUCuNVA2OzFizszN	MmWyV2FPT0WU
BB65-RCC	M{XyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XtXmlEPTB;MD6xNFU2PCEQvF2=	MYPTRW5ITVJ?
NKM-1	MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGC5dJFKSzVyPUCuNVA3PjZizszN	M1LrRnNCVkeHUh?=
HD-MY-Z	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzaVYxKSzVyPUCuNVA5PzNizszN	NGHLZpNUSU6JRWK=
TGBC11TKB	NX[yUXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMUC5NFMh\|ryP	MlTMV2FPT0WU
COLO-679	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMUGyNVEh\|ryP	NFnyeI9USU6JRWK=
TE-8	NFrQWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;CWmlEPTB;MD6xNVI3PCEQvF2=	NXjVOo5HW0GQR1XS
SK-MEL-28	M{fmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;Je\|E3UUN3ME2wMlEyOzJzIN88US=>	NUnVRVNzW0GQR1XS
SH-4	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLCWo9WUUN3ME2wMlEyOzV4IN88US=>	NGfJVpBUSU6JRWK=
KALS-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMUGzPVMh\|ryP	M2n3enNCVkeHUh?=
RKO	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fheWlEPTB;MD6xNVc3PCEQvF2=	MXzTRW5ITVJ?
OMC-1	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrwNXRKSzVyPUCuNVE4QTdizszN	NYfBXnNLW0GQR1XS
BT-549	NFL5e\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfpTWM2OD1yLkGxO\|k6KM7:TR?=	NUXEU\|lKW0GQR1XS
NCI-H28	NGq3UoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH20dIxKSzVyPUCuNVE5OTdizszN	NG\VWFFUSU6JRWK=
RXF393	M3TVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMUG5PFIh\|ryP	MYjTRW5ITVJ?
COLO-829	NGXMcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1uxeGlEPTB;MD6xNlAxPSEQvF2=	NX;tNWNJW0GQR1XS
HMV-II	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfVU4hKSzVyPUCuNVIxOiEQvF2=	NHTWVI1USU6JRWK=
SW1990	NFfx[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMUKxOVch\|ryP	NVvGOHREW0GQR1XS
NCI-H1437	NVS2To1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWC3[YhoUUN3ME2wMlEzOTV5IN88US=>	NHXMPJJUSU6JRWK=
SNB75	MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DtPGlEPTB;MD6xNlE3QSEQvF2=	NFrNc\|hUSU6JRWK=
EW-3	NUG5WYVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4r2[mlEPTB;MD6xNlY3OSEQvF2=	NE[y[FBUSU6JRWK=
SAS	MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYD3O4g2UUN3ME2wMlEzPjlizszN	M173R3NCVkeHUh?=
NCI-H1666	M{fPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:3TWM2OD1yLkGyO\|c1KM7:TR?=	MVHTRW5ITVJ?
A375	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMUK3O\|gh\|ryP	NWS2[YdPW0GQR1XS
CAMA-1	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm2TWM2OD1yLkGyPVI1KM7:TR?=	MXHTRW5ITVJ?
HuP-T4	NV35blBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMUK5OFMh\|ryP	M3XSNnNCVkeHUh?=
NCI-H292	NGnZZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMUOxNUDPxE1?	MWnTRW5ITVJ?
PC-14	NHj1e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHMRZJDUUN3ME2wMlE{OjFzIN88US=>	M3TDTHNCVkeHUh?=
BPH-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMUO0NUDPxE1?	NHu2VWdUSU6JRWK=
GAK	NWXIPFBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojsTWM2OD1yLkGzOVY4KM7:TR?=	NFvIXlNUSU6JRWK=
VMRC-RCZ	MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTmUohKSzVyPUCuNVM4PjJizszN	NUnHN3gyW0GQR1XS
SK-MEL-24	M3rhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HLb2lEPTB;MD6xN\|g4KM7:TR?=	MW\TRW5ITVJ?
LB831-BLC	M3HENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMUO4PFMh\|ryP	NVrRZ211W0GQR1XS
NCI-H2452	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mny1TWM2OD1yLkGzPVU3KM7:TR?=	MV7TRW5ITVJ?
RT-112	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjSXmpPUUN3ME2wMlE1ODN3IN88US=>	M3OwT3NCVkeHUh?=
GP5d	NVvvbVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMUSxNFQh\|ryP	NXP3eIxzW0GQR1XS
LC-2-ad	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfHTWM2OD1yLkG0NVIyKM7:TR?=	NFnUU3RUSU6JRWK=
MPP-89	NIHXWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TaNGlEPTB;MD6xOFEzPSEQvF2=	NGX4RZdUSU6JRWK=
NUGC-3	NHHycnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHEeW1KSzVyPUCuNVQ1PzhizszN	M4L6WXNCVkeHUh?=
GI-1	M1zKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITDXHFKSzVyPUCuNVQ2PThizszN	NIjOVHhUSU6JRWK=
HCC1419	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13ONmlEPTB;MD6xOFU4PiEQvF2=	M4\o[HNCVkeHUh?=
SW1573	M3TTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnywTWM2OD1yLkG0O\|U5KM7:TR?=	NFrtPG9USU6JRWK=
NCI-H2347	M4D2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{e5W2lEPTB;MD6xOFg{QSEQvF2=	NX2wdGtuW0GQR1XS
Mewo	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLTTWM2OD1yLkG0PFg6KM7:TR?=	NFPpZ2hUSU6JRWK=
639-V	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMUWwNVMh\|ryP	MlLxV2FPT0WU
AsPC-1	NIXjcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrMboFsUUN3ME2wMlE2OjJ3IN88US=>	M3LvfXNCVkeHUh?=
NCI-H1648	M4rrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\XWYduUUN3ME2wMlE2OjN{IN88US=>	NFzXfnBUSU6JRWK=
786-0	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIH2fY1KSzVyPUCuNVU{QDFizszN	M1L2bHNCVkeHUh?=
ETK-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMUW5JO69VQ>?	M4LVcXNCVkeHUh?=
BxPC-3	M{HHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMUW5OlYh\|ryP	NF7rSGNUSU6JRWK=
CAL-62	NYLNV45oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NISxTItKSzVyPUCuNVYyPjlizszN	NWi2emE2W0GQR1XS
HCC1937	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3GZYhKSzVyPUCuNVYzPzVizszN	NXv6VolQW0GQR1XS
NCI-H1299	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PMRmlEPTB;MD6xOlI5PSEQvF2=	NH3TTWpUSU6JRWK=
SW1088	M4nSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXxSnRKSzVyPUCuNVY1OTNizszN	MkLNV2FPT0WU
FTC-133	NUTYfWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS0b4doUUN3ME2wMlE3PTRizszN	NY\DTW1PW0GQR1XS
OC-314	M1PD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TpSWlEPTB;MD6xOlY6KM7:TR?=	MVrTRW5ITVJ?
SCC-9	M4T2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\UdGlEPTB;MD6xOlcyPiEQvF2=	MnrZV2FPT0WU
HT-1376	NHzTcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDMTWM2OD1yLkG2PVM3KM7:TR?=	MUDTRW5ITVJ?
U-2-OS	M1nsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWf5SIs3UUN3ME2wMlE4OTd\|IN88US=>	MYnTRW5ITVJ?
COLO-824	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrrc5ByUUN3ME2wMlE4Ojl2IN88US=>	MnzvV2FPT0WU
BB30-HNC	M{DndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMUezN{DPxE1?	MX3TRW5ITVJ?
NCI-H2087	MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnq4TWM2OD1yLkG3N\|Y5KM7:TR?=	NVnjUVFTW0GQR1XS
NCI-H2170	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HYOWlEPTB;MD6xO\|U{PiEQvF2=	Ml;kV2FPT0WU
SK-OV-3	NG\TWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMUe1O\|Eh\|ryP	M1i2SnNCVkeHUh?=
MZ7-mel	NUHHSoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXHVIxQUUN3ME2wMlE4PjR7IN88US=>	NETEXpFUSU6JRWK=
NCI-H650	NWPocVhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMUe2PFIh\|ryP	NX3NUGtKW0GQR1XS
KOSC-2	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMUe3N\|Qh\|ryP	NIW3O5JUSU6JRWK=
SCC-4	NFfBVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3IVG9xUUN3ME2wMlE4Pzd5IN88US=>	M3\RNnNCVkeHUh?=
MDA-MB-157	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzPcVlHUUN3ME2wMlE5ODh{IN88US=>	M37jcXNCVkeHUh?=
KYSE-520	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnGTWM2OD1yLkG4NkDPxE1?	M1XncnNCVkeHUh?=
LK-2	NXjqNVlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LncWlEPTB;MD6xPFMxOyEQvF2=	NWXxWlBsW0GQR1XS
KNS-81-FD	M1fCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMUizPVQh\|ryP	NES3RZNUSU6JRWK=
IGROV-1	NVq0SmpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DofGlEPTB;MD6xPFQ1OyEQvF2=	NV;MPVJRW0GQR1XS
DEL	NXTqbVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULZfYdMUUN3ME2wMlE5PDVizszN	MlHDV2FPT0WU
NCI-H1395	MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMUi2PFIh\|ryP	NF[x[oxUSU6JRWK=
JEG-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMUi3NFUh\|ryP	MVTTRW5ITVJ?
BCPAP	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMUi4O\|Ih\|ryP	MlXaV2FPT0WU
CAL-27	NHPkVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Po[WlEPTB;MD6xPVAzOiEQvF2=	MkHXV2FPT0WU
RD	NXnYfpJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjZTWM2OD1yLkG5NVE{KM7:TR?=	M1rpOnNCVkeHUh?=
RVH-421	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LtSmlEPTB;MD6xPVEyPiEQvF2=	MnXkV2FPT0WU
Capan-2	NYnqdHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PS[GlEPTB;MD6xPVI2PiEQvF2=	NEXESlJUSU6JRWK=
COLO-680N	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXPTWM2OD1yLkG5N\|Y1KM7:TR?=	M2D0fHNCVkeHUh?=
NCI-H1650	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMkCwOVch\|ryP	MV\TRW5ITVJ?
SBC-5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLpTWM2OD1yLkKwNVE5KM7:TR?=	MnLBV2FPT0WU
U031	NUjJbXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMkC1OFch\|ryP	NGC4dWJUSU6JRWK=
S-117	M{[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET1R2RKSzVyPUCuNlA2PjRizszN	NWTZdJRRW0GQR1XS
DoTc2-4510	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHqOZRKSzVyPUCuNlA4PjlizszN	M{TPSHNCVkeHUh?=
AM-38	NIXSTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rTPGlEPTB;MD6yNFg1QCEQvF2=	NGjDZ4VUSU6JRWK=
A172	NH7yOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[zfoFoUUN3ME2wMlIyODJ{IN88US=>	NUn4SoJuW0GQR1XS
HPAF-II	NEDS[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITDN45KSzVyPUCuNlEzPjRizszN	NI\ETnpUSU6JRWK=
769-P	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j4W2lEPTB;MD6yNVI5KM7:TR?=	NX2wZll3W0GQR1XS
MFE-280	M2PwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4C5PWlEPTB;MD6yNVI6QCEQvF2=	MYHTRW5ITVJ?
TE-9	M{HTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHf1ToNKSzVyPUCuNlE4QDZizszN	MWrTRW5ITVJ?
C2BBe1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DobGlEPTB;MD6yNlE6KM7:TR?=	NGjHVGJUSU6JRWK=
EoL-1-cell	NIq0Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDPTWM2OD1yLkKyNlA{KM7:TR?=	MkPZV2FPT0WU
G-361	M2LJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX3OmNKSzVyPUCuNlI3QDJizszN	NUTCZohGW0GQR1XS
KYSE-270	M3frN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHex[FNKSzVyPUCuNlMxQDRizszN	M3f2W3NCVkeHUh?=
TK10	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMkOxNVch\|ryP	NILpb\|NUSU6JRWK=
ML-2	NFjrN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn65TWM2OD1yLkKzNVE6KM7:TR?=	MoDUV2FPT0WU
MHH-ES-1	NXzi[o5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zVN2lEPTB;MD6yN\|Y5OSEQvF2=	MlvCV2FPT0WU
BHY	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXhTWM2OD1yLkKzOlkyKM7:TR?=	Ml;0V2FPT0WU
LS-513	NULaUWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTQTWM2OD1yLkKzPVYyKM7:TR?=	NX7lXY1UW0GQR1XS
COLO-678	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHKR3NNUUN3ME2wMlI1ODR2IN88US=>	NHq3bFVUSU6JRWK=
NCI-H747	M3rKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfse3hKSzVyPUCuNlQyPjlizszN	Mnm5V2FPT0WU
K5	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMkSzPEDPxE1?	NYDNdI94W0GQR1XS
OS-RC-2	M4S2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rBXGlEPTB;MD6yOFUxQSEQvF2=	MYnTRW5ITVJ?
KINGS-1	NX32ZVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfHXGV5UUN3ME2wMlI1PTJ7IN88US=>	NH3Pe5NUSU6JRWK=
SCC-25	NULiXJlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMkS1OlMh\|ryP	MVrTRW5ITVJ?
CAPAN-1	NWD0SXdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMkS3PFMh\|ryP	NYPFO5FNW0GQR1XS
ESS-1	NES4NW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXCWotKSzVyPUCuNlQ5ODVizszN	M{\CUnNCVkeHUh?=
TE-6	NXznW3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXOWFVzUUN3ME2wMlI2PzVizszN	MXXTRW5ITVJ?
LB2518-MEL	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLkTWM2OD1yLkK1O\|c4KM7:TR?=	MlHvV2FPT0WU
COLO-800	M{KzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljTTWM2OD1yLkK1PFEzKM7:TR?=	Ml\YV2FPT0WU
LU-134-A	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMk[xN\|Yh\|ryP	MoXIV2FPT0WU
NCI-H1155	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW4dWtKSzVyPUCuNlYyPjJizszN	MnO2V2FPT0WU
MFM-223	NGj2WpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHBOnBKSzVyPUCuNlY{PjNizszN	MYnTRW5ITVJ?
HTC-C3	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTl[WdwUUN3ME2wMlI3PTB4IN88US=>	MlvHV2FPT0WU
HCT-116	NGOxXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLETWM2OD1yLkK2OVk6KM7:TR?=	MYLTRW5ITVJ?
Ca-Ski	NGPmd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX73e2F{UUN3ME2wMlI3Pjd6IN88US=>	MmLNV2FPT0WU
SBC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwMk[3OFIh\|ryP	MlGxV2FPT0WU
NB69	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\heGlEPTB;MD6yO\|A5PyEQvF2=	NEPucWlUSU6JRWK=
J82	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG3Omx7UUN3ME2wMlI4OjZ3IN88US=>	NGjUR5hUSU6JRWK=
U-118-MG	NVXT[2gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fsVWlEPTB;MD6yO\|U4QSEQvF2=	M2LP[XNCVkeHUh?=
NCI-H1355	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3u1N2lEPTB;MD6yPFA4PCEQvF2=	M{nWc3NCVkeHUh?=
NCI-H1048	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMki5OVYh\|ryP	NWG1S\|Q5W0GQR1XS
SW954	NGOwN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3UTFhKSzVyPUCuNlkzOjdizszN	M3zCZ3NCVkeHUh?=
NMC-G1	NHPyWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMkmyO\|ch\|ryP	MoXwV2FPT0WU
SW1710	NG[wWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMkm0PVQh\|ryP	NIDIVHBUSU6JRWK=
KY821	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILRR4JKSzVyPUCuNlk5PzJizszN	MYfTRW5ITVJ?
HCC38	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwM{CwO\|gh\|ryP	NEHvc5RUSU6JRWK=
NCI-SNU-5	NV3ZOoE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjJRotKSzVyPUCuN\|A2PCEQvF2=	NVrRWoQ5W0GQR1XS
ES8	M3HHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvhTWM2OD1yLkOwO\|g1KM7:TR?=	M17wRnNCVkeHUh?=
COLO-792	M{DrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3X5[2lEPTB;MD6zNVI2OSEQvF2=	NVnoZopkW0GQR1XS
BFTC-905	M4G5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn20TWM2OD1yLkOxOVIyKM7:TR?=	NYHobXViW0GQR1XS
ChaGo-K-1	NVHHbnU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq2TWM2OD1yLkOxO\|E2KM7:TR?=	MVLTRW5ITVJ?
Daoy	NFm1SlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjHVJk3UUN3ME2wMlMyPzJ\|IN88US=>	MVTTRW5ITVJ?
SJSA-1	NFnMTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXexWZUyUUN3ME2wMlMyQDR5IN88US=>	MmfpV2FPT0WU
KNS-62	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TsUWlEPTB;MD6zNlA5QCEQvF2=	MljlV2FPT0WU
CAKI-1	NEi5VpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETQeXJKSzVyPUCuN\|IyOTFizszN	NXrWSXZQW0GQR1XS
UACC-62	NYDN[3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGP1eWVKSzVyPUCuN\|IzOjdizszN	MmnSV2FPT0WU
HuCCT1	M4\RRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwM{KyPFMh\|ryP	M4j1eXNCVkeHUh?=
CTB-1	M4fGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknKTWM2OD1yLkOyO\|U{KM7:TR?=	NInySI5USU6JRWK=
NTERA-S-cl-D1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonmTWM2OD1yLkOyPFM3KM7:TR?=	MlPIV2FPT0WU
T-24	NVXKSXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwM{OxOVkh\|ryP	MVXTRW5ITVJ?
KYSE-70	M3;yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwM{OyPFMh\|ryP	Mk\1V2FPT0WU
SW626	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrq[pBKSzVyPUCuN\|M2OzJizszN	MUDTRW5ITVJ?
LB996-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWwVFlKSzVyPUCuN\|M3OTlizszN	MWPTRW5ITVJ?
DMS-273	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXpTWM2OD1yLkOzPVE3KM7:TR?=	M4\McXNCVkeHUh?=
SW1783	NFu3UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPITWM2OD1yLkOzPVk4KM7:TR?=	MVrTRW5ITVJ?
KU812	NFzs[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEftdGNKSzVyPUCuN\|QxOzhizszN	MVPTRW5ITVJ?
HSC-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwM{SwOVMh\|ryP	NGX0SVBUSU6JRWK=
A3-KAW	NVTuU2t{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwM{SxOlIh\|ryP	NEHOeGJUSU6JRWK=
COLO-684	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwM{S1NFEh\|ryP	MknYV2FPT0WU
NCI-H2405	M1;KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7jTWM2OD1yLkO0OlMyKM7:TR?=	MYPTRW5ITVJ?
NCI-H2228	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HpOmlEPTB;MD6zOVM2PyEQvF2=	M{DkO3NCVkeHUh?=
NB13	M1vPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7aNYg2UUN3ME2wMlM3QDJ7IN88US=>	MmXkV2FPT0WU
no-11	M4\MWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7YXWhzUUN3ME2wMlM3QTVizszN	MX;TRW5ITVJ?
DK-MG	NVjRTG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEf3WXlKSzVyPUCuN\|cyQDhizszN	NWDGUYpCW0GQR1XS
NBsusSR	MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\BWmlEPTB;MD6zO\|I5PSEQvF2=	M1P3cXNCVkeHUh?=
KP-N-YS	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\sTWM2OD1yLkO3OFY{KM7:TR?=	NVnFR\|lnW0GQR1XS
CFPAC-1	NIXreHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwM{e1NVgh\|ryP	M1;0dXNCVkeHUh?=
KARPAS-45	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjmcHRKSzVyPUCuN\|c5PjJizszN	NIC2NHpUSU6JRWK=
NCI-H1793	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nQ[2lEPTB;MD6zPFUyKM7:TR?=	M3vpenNCVkeHUh?=
HCE-T	M2P4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlGzTWM2OD1yLkO4OlA{KM7:TR?=	M4fNNXNCVkeHUh?=
NCI-H520	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Xk[mlEPTB;MD6zPFcxOyEQvF2=	MkD5V2FPT0WU
HCC2157	NUnmZ4ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrNRZJEUUN3ME2wMlM5PzhzIN88US=>	NETk[plUSU6JRWK=
EW-18	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwM{i5OFEh\|ryP	MonSV2FPT0WU
RO82-W-1	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmf4TWM2OD1yLkO5Olk6KM7:TR?=	MXnTRW5ITVJ?
HuP-T3	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\RTWM2OD1yLkSwNVQ{KM7:TR?=	MVTTRW5ITVJ?
PANC-10-05	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwNEGxO{DPxE1?	NVnSW2lCW0GQR1XS
NCI-H1703	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PUU2lEPTB;MD60NVQ1PiEQvF2=	NXvENIlMW0GQR1XS
TE-10	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D2bWlEPTB;MD60NVQ1PyEQvF2=	MVzTRW5ITVJ?
HOS	NFzBTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[2SIlKSzVyPUCuOFE3QDJizszN	MUjTRW5ITVJ?
LN-405	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTZZ4tEUUN3ME2wMlQyPjh5IN88US=>	NW\2SodpW0GQR1XS
A427	NWr1SVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ruZmlEPTB;MD60NVk5OSEQvF2=	NIP2OJRUSU6JRWK=
CAL-12T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwNEK3PEDPxE1?	MoS5V2FPT0WU
SW756	NHi1PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlixTWM2OD1yLkS0NVg{KM7:TR?=	MWHTRW5ITVJ?
YAPC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7tTWM2OD1yLkS1NFgh\|ryP	MnXHV2FPT0WU
GOTO	NVzSSmdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X4NWlEPTB;MD60OVE3KM7:TR?=	M3flTHNCVkeHUh?=
C3A	M2\yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3qxUGlEPTB;MD60OVQ{PyEQvF2=	MlrSV2FPT0WU
UM-UC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUK3WGRCUUN3ME2wMlQ2PDdizszN	MUjTRW5ITVJ?
NCI-H1573	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwNEW1Olkh\|ryP	MUTTRW5ITVJ?
LS-411N	M3fsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nIXWlEPTB;MD60OlUzPyEQvF2=	NGDZcIhUSU6JRWK=
COR-L23	M2H5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu1XVNKSzVyPUCuOFY4PjRizszN	NIT0S2RUSU6JRWK=
HCE-4	NXjqS\|NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTu[G04UUN3ME2wMlQ4PDR4IN88US=>	MXPTRW5ITVJ?
NCI-H2291	M1jMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHZTWM2OD1yLkS3PFk3KM7:TR?=	MnTUV2FPT0WU
A101D	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlraTWM2OD1yLkS4NFU{KM7:TR?=	NXvESmpLW0GQR1XS
HT-3	M4\2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DvfmlEPTB;MD60PFIyPyEQvF2=	NXnnW5BGW0GQR1XS
HOP-62	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwNEm4OlUh\|ryP	MXTTRW5ITVJ?
PC-3	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\oSHBsUUN3ME2wMlUyPTB5IN88US=>	NHrGcJJUSU6JRWK=
CTV-1	Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33MV2lEPTB;MD61NlY3QSEQvF2=	NV7VSVZqW0GQR1XS
PANC-08-13	M{DYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HpeWlEPTB;MD61N\|E4PyEQvF2=	M1HjT3NCVkeHUh?=
CAL-120	M17wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzUS2tlUUN3ME2wMlU{Ozl7IN88US=>	MVrTRW5ITVJ?
UMC-11	NUG5ZngzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1m5RWlEPTB;MD61OVI{PCEQvF2=	NFvye\|FUSU6JRWK=
MSTO-211H	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TTcWlEPTB;MD61OVc3OiEQvF2=	MkeyV2FPT0WU
NCI-H2126	NIfQ[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2L6NmlEPTB;MD61OlgyPSEQvF2=	NVvVd5U6W0GQR1XS
SNU-C2B	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPWZm56UUN3ME2wMlU4QTd5IN88US=>	M3f0cXNCVkeHUh?=
DBTRG-05MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwNUiwOVMh\|ryP	NXnae4ZZW0GQR1XS
MKN1	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvKU4hqUUN3ME2wMlU5Pzh\|IN88US=>	NF3GZ\|RUSU6JRWK=
ES3	M2rwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13EemlEPTB;MD61PVEzPCEQvF2=	NEXpe5ZUSU6JRWK=
OVCAR-3	NYXvWFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLxTop5UUN3ME2wMlU6OzRzIN88US=>	NWLK[41KW0GQR1XS
ACHN	M{DPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwNkC1Olkh\|ryP	MUHTRW5ITVJ?
SW872	NUjOcIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjodm1KSzVyPUCuOlA4PjNizszN	MX\TRW5ITVJ?
CP66-MEL	M2jhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3Tc2c1UUN3ME2wMlYxQTZ7IN88US=>	MYDTRW5ITVJ?
NCI-H661	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnFNVlYUUN3ME2wMlYyOTB2IN88US=>	MULTRW5ITVJ?
UACC-893	M4G5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;MTWM2OD1yLk[zOlgyKM7:TR?=	M4f2THNCVkeHUh?=
JVM-3	NFrDbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwNkO4NFQh\|ryP	Mln0V2FPT0WU
SF268	M2foRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr3TWM2OD1yLk[0N\|Q6KM7:TR?=	NH;ZW4FUSU6JRWK=
OCI-AML2	NILVOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:1TWM2OD1yLk[1N\|k4KM7:TR?=	MnHrV2FPT0WU
RPMI-8226	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3ZVYNPUUN3ME2wMlY3OzJ\|IN88US=>	M1j1bXNCVkeHUh?=
MKN28	NXTPfYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwNk[2NlQh\|ryP	NIXycHZUSU6JRWK=
MDA-MB-453	NUK3[4o3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNkexPEDPxE1?	NXO1[\|BZW0GQR1XS
BV-173	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[0bYlmUUN3ME2wMlY5Pjd7IN88US=>	M{LXRXNCVkeHUh?=
NCI-H358	M1OwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLwOnlKSzVyPUCuOlg4OjZizszN	NV;TfWxbW0GQR1XS
NCI-H1651	MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwNzFOwG0>	NYXwTWhDW0GQR1XS
MDA-MB-415	NYDmRWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rjZ2lEPTB;MD63NFgzQSEQvF2=	NEH6XoNUSU6JRWK=
8305C	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwN{K0PVgh\|ryP	NIDDTGZUSU6JRWK=
EFM-19	NGe3RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLBTWM2OD1yLkezOlcyKM7:TR?=	NHjqd25USU6JRWK=
RERF-LC-MS	M3\lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;GV2lEPTB;MD63OFYyOyEQvF2=	MmTLV2FPT0WU
A388	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7CTWM2OD1yLke2OFY4KM7:TR?=	NHLRb5NUSU6JRWK=
GI-ME-N	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjWTWM2OD1yLke3NlM2KM7:TR?=	MmTHV2FPT0WU
IGR-1	NHjlfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWizdHBoUUN3ME2wMlc6ODR\|IN88US=>	MV3TRW5ITVJ?
LNCaP-Clone-FGC	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TB[mlEPTB;MD64NFAxPCEQvF2=	NXHCblh2W0GQR1XS
SK-MEL-3	M2njdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInSTIhKSzVyPUCuPFE2ODhizszN	M4GxTHNCVkeHUh?=
UACC-257	NEXsTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwOEKyN\|Eh\|ryP	MWXTRW5ITVJ?
OE33	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXp[5IxUUN3ME2wMlg2OTBzIN88US=>	MkXRV2FPT0WU
QIMR-WIL	NXGyZoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwOEWxOFEh\|ryP	MXPTRW5ITVJ?
NCI-H2009	M1TOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTZZZlKSzVyPUCuPFU{OTFizszN	NITEVI9USU6JRWK=
NCI-H522	M13KN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PuXWlEPTB;MD64O\|c5OyEQvF2=	M{Tzd3NCVkeHUh?=
Saos-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwOEe4O\|Eh\|ryP	NY\HUFJYW0GQR1XS
NB17	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7ITWM2OD1yLki4NFI2KM7:TR?=	MoHNV2FPT0WU
D-392MG	NEfjUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwOEmzOVYh\|ryP	M{\seXNCVkeHUh?=
SHP-77	NFjCZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\SdoZZUUN3ME2wMlkxPDh3IN88US=>	MUXTRW5ITVJ?
SK-MEL-30	M4\DT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnBTWM2OD1yLkmxNVg2KM7:TR?=	MXXTRW5ITVJ?
GCIY	NFrsTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zCemlEPTB;MD65NVg1OyEQvF2=	M1XXenNCVkeHUh?=
HCC70	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETydWZKSzVyPUCuPVIxPTlizszN	Ml3SV2FPT0WU
LU-65	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwOUK1PVEh\|ryP	MlT1V2FPT0WU
NCI-H1563	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwOUS4OlUh\|ryP	MoHMV2FPT0WU
KURAMOCHI	M{\XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M121UWlEPTB;MD65OVE6OiEQvF2=	NFmwfGNUSU6JRWK=
PA-1	NWXqVoI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfoTWM2OD1yLkm1OFI1KM7:TR?=	M3yy[XNCVkeHUh?=
NOS-1	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fFc2lEPTB;MD65O\|Q5QSEQvF2=	MlfIV2FPT0WU
NCI-H69	M2j4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TaNmlEPTB;MD65O\|Y{PCEQvF2=	MljQV2FPT0WU
KYSE-450	M3izV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjobYpKSzVyPUCuPVg3OjZizszN	MmHQV2FPT0WU
8505C	M3noZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:0OYdJUUN3ME2wMlk6QTh{IN88US=>	NYj6U4RNW0GQR1XS
TGBC24TKB	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4ToeGlEPTB;MT6wNFA5PCEQvF2=	MVnTRW5ITVJ?
PFSK-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXGNoNKSzVyPUGuNFE1OjhizszN	NXKyZVU3W0GQR1XS
EKVX	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\2UlJKUUN3ME2xMlA{OTJzIN88US=>	Ml7lV2FPT0WU
RCM-1	M335b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTFwMEW1NFch\|ryP	NEGwcnZUSU6JRWK=
SW900	NHnyfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX6TWM2OD1zLkC3PFMh\|ryP	MYHTRW5ITVJ?
D-542MG	NVLUZmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7tWZlKSzVyPUGuNFc5PTVizszN	NWXF[VA1W0GQR1XS
SK-PN-DW	NV:wNm1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fVNWlEPTB;MT6xNFA2PiEQvF2=	MV7TRW5ITVJ?
NCI-H727	NEOyc\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTFwMUCxOVQh\|ryP	NGDuN3pUSU6JRWK=
SW837	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnnTWM2OD1zLkGwPVU1KM7:TR?=	MY\TRW5ITVJ?
BT-20	NWTqRZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPEb\|ZKSzVyPUGuNVEzODRizszN	MmLqV2FPT0WU
RH-18	NYnURld6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj4bHRKSzVyPUGuNVMyODNizszN	Ml;YV2FPT0WU
TE-12	NHzacnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO4dopKSzVyPUGuNVM{OzNizszN	M2TEOHNCVkeHUh?=
NB10	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTFwMUOzOFQh\|ryP	MoD2V2FPT0WU
AU565	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTFwMUW5O\|Mh\|ryP	MoK4V2FPT0WU
OAW-42	NInTdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\nTWM2OD1zLkG4N\|A3KM7:TR?=	NFXLWWFUSU6JRWK=
DJM-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LES2lEPTB;MT6xPVg5OSEQvF2=	NHrU[plUSU6JRWK=
HH	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jHcmlEPTB;MT6yN\|g{OSEQvF2=	MXrTRW5ITVJ?
LAMA-84	NG\E[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH1Z\|hKSzVyPUGuNlc{QTRizszN	NFG2dI9USU6JRWK=
KNS-42	M{TTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HLbmlEPTB;MT6zNFI6PiEQvF2=	MYrTRW5ITVJ?
NCI-H2052	NVfKOZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn30TWM2OD1zLkOwOVA4KM7:TR?=	M3fYR3NCVkeHUh?=
MLMA	NFH3cJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfZUI1iUUN3ME2xMlMzPDB5IN88US=>	NGPHRZZUSU6JRWK=
NB12	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zleGlEPTB;MT6zOVY{PiEQvF2=	MY\TRW5ITVJ?
NCI-H1838	NFPKeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTmTWM2OD1zLkO2N\|A3KM7:TR?=	M1LJTXNCVkeHUh?=
NCI-H526	M2nocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzi[oRpUUN3ME2xMlM4QDV\|IN88US=>	NXvVW3BGW0GQR1XS
LS-123	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS2fFZnUUN3ME2xMlM6ODl2IN88US=>	MWTTRW5ITVJ?
HDLM-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDBTWM2OD1zLkO5NlcyKM7:TR?=	NXL4R\|FTW0GQR1XS
MC-IXC	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTOWGRKSzVyPUGuOFI{PzFizszN	MlrtV2FPT0WU
HCT-15	M1u1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLRTWM2OD1zLkSzNFY5KM7:TR?=	MnnVV2FPT0WU
NCI-H596	MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWThOJRrUUN3ME2xMlQ2ODZzIN88US=>	MmLVV2FPT0WU
ZR-75-30	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIX2XJlKSzVyPUGuOFcxQDJizszN	M2rHVnNCVkeHUh?=
A704	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3frTmlEPTB;MT62OlU3OyEQvF2=	M2\0XnNCVkeHUh?=
OVCAR-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvwTWM2OD1zLk[5OlA4KM7:TR?=	M4XWZnNCVkeHUh?=
SW1417	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTFwN{K4OFkh\|ryP	NUfWc5Z7W0GQR1XS
CAS-1	M3\Yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFGy[YRKSzVyPUGuO\|M6OzZizszN	MXXTRW5ITVJ?
IST-SL1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4foNmlEPTB;MT63PVc2QSEQvF2=	M1WyenNCVkeHUh?=
A253	NEj3VY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEL2VXNKSzVyPUGuPFIzOzlizszN	Mmj0V2FPT0WU
EW-16	NFfTV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFwOEK4O\|Uh\|ryP	NGLlSVBUSU6JRWK=
SK-NEP-1	M4LTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PsZmlEPTB;MT64Olk5QCEQvF2=	NUjxS2VvW0GQR1XS
NCI-H226	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwOEmzOVkh\|ryP	NYPycY9QW0GQR1XS
HOP-92	M4PaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PVTWlEPTB;MT65OlA6QSEQvF2=	M{fPU3NCVkeHUh?=
NCI-H441	NXfNTYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7uSIFKSzVyPUKuNFI{OzdizszN	NVryOI1WW0GQR1XS
LU-139	NVLEUZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnsTWM2OD1{LkCzNVE1KM7:TR?=	NYnDXVhmW0GQR1XS
SJRH30	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fVe2lEPTB;Mj6wOFI2OyEQvF2=	NGXXfnlUSU6JRWK=
MG-63	M3;JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\3d5hKSzVyPUKuNVQyOTFizszN	MlvnV2FPT0WU
NH-12	NFP2S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXBOHRKSzVyPUKuNVUxODZizszN	NXLHXmZ{W0GQR1XS
NB7	NUXxWHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vycmlEPTB;Mj6xPVY4OyEQvF2=	NUnvNoF3W0GQR1XS
LB771-HNC	NYHIT5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJwMkC1PVUh\|ryP	NIDBc5BUSU6JRWK=
HCC1569	M3m0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XXPGlEPTB;Mj6yOFU5OyEQvF2=	MVzTRW5ITVJ?
D-283MED	NHvn[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXYTWM2OD1{LkK0O\|gzKM7:TR?=	MoLBV2FPT0WU
J-RT3-T3-5	NEXYR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTJwMkWzOVEh\|ryP	MlTpV2FPT0WU
ATN-1	M2TUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEX2OphKSzVyPUKuN\|MxQDJizszN	NFK5[ItUSU6JRWK=
HCC1954	NV7MOVA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PRe2lEPTB;Mj6zOFQxQCEQvF2=	NY\hNIxsW0GQR1XS
SCC-15	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HLRmlEPTB;Mj6zPVMyOiEQvF2=	NE\TblNUSU6JRWK=
COLO-668	M1nIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnO3TWM2OD1{LkSzNkDPxE1?	MmH2V2FPT0WU
LB373-MEL-D	NXjjUW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Gxc2lEPTB;Mj61OFY4PyEQvF2=	Mk[yV2FPT0WU
no-10	NVzLRWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPyfYFQUUN3ME2yMlU1QTR5IN88US=>	NHvCcXFUSU6JRWK=
HT-1197	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;EdIQ3UUN3ME2yMlY{OTh6IN88US=>	MkLIV2FPT0WU
DU-145	M4HUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;1TWM2OD1{Lke5NVYzKM7:TR?=	MVnTRW5ITVJ?
SK-N-AS	NYLlSYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\LNGlEPTB;Mj64OFY6OiEQvF2=	NEjlS4tUSU6JRWK=
MOLT-4	NFXNS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYO5Wng{UUN3ME2yMlg2OzJ{IN88US=>	MljIV2FPT0WU
EW-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTyTWM2OD1{LkmyPFQyKM7:TR?=	NYHzcWdUW0GQR1XS
DB	NITR[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjiTZJKSzVyPUKuPVc4PTlizszN	MmSyV2FPT0WU
HL-60	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfEe4JKSzVyPUOuNFQ{PzZizszN	NF2xXHlUSU6JRWK=
SK-N-DZ	M4LhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTNwMEWwO\|Uh\|ryP	NFi5PYxUSU6JRWK=
NY	NWO0OFhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\SOGlEPTB;Mz6wPFU1OiEQvF2=	NF;zfFVUSU6JRWK=
T47D	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknmTWM2OD1\|LkGwOVU5KM7:TR?=	NIf4V\|NUSU6JRWK=
NCI-H2029	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTNwMkK0O\|ch\|ryP	M3e0NXNCVkeHUh?=
KARPAS-299	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmSzTWM2OD1\|LkK2NFI4KM7:TR?=	NYLZ[HkzW0GQR1XS
KM-H2	M{C0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3UOXRKSzVyPUOuN\|A3QCEQvF2=	NETSRoNUSU6JRWK=
CHP-134	NUOwbGFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTNwNEezPUDPxE1?	M{HzSXNCVkeHUh?=
22RV1	NVzlS3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLt[3VKSzVyPUOuOFkyPjhizszN	NIrxT3FUSU6JRWK=
NB5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTNwNUC2PFkh\|ryP	MVrTRW5ITVJ?
CW-2	NHLLNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTNwNUWzNVQh\|ryP	NVfxToVGW0GQR1XS
EFO-21	NVXNZ\|FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTNwNU[5OEDPxE1?	M3nLWHNCVkeHUh?=
HuH-7	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTNwNUi0NVQh\|ryP	MYfTRW5ITVJ?
ALL-PO	NXv3WY57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3W0VmlEPTB;Mz62NlM{PSEQvF2=	Mly1V2FPT0WU
EM-2	M1myPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnzV\|dpUUN3ME2zMlY6ODFzIN88US=>	MnHzV2FPT0WU
KLE	M4fFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTNwN{OwNlkh\|ryP	M3r1[nNCVkeHUh?=
NEC8	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLHTWM2OD1\|LkmxPFA5KM7:TR?=	NYX4THp4W0GQR1XS
KP-N-YN	NXvJVIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzrdnhTUUN3ME2zMlk{PDd4IN88US=>	M2PPNXNCVkeHUh?=
SK-MEL-1	NVv6ZWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTRwMEO1NVgh\|ryP	MWXTRW5ITVJ?
CAL-54	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHDZpFlUUN3ME20MlA2QTFizszN	NGXwVYlUSU6JRWK=
MS-1	M3u5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2q2XGlEPTB;ND6xOlE2PSEQvF2=	MU\TRW5ITVJ?
NCI-H209	M2rlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\zTGlEPTB;ND6yPVk6QSEQvF2=	MnG5V2FPT0WU
NOMO-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1W0XmlEPTB;ND6zNlE{OSEQvF2=	NEHYSHlUSU6JRWK=
RPMI-2650	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;YTWM2OD12LkO2N\|I4KM7:TR?=	M4jLW3NCVkeHUh?=
NCI-H810	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\VU\|BKSzVyPUSuN\|k4OzZizszN	M{LT[XNCVkeHUh?=
Ca9-22	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvlO4ZKSzVyPUSuOFU3QTFizszN	NWezOWxoW0GQR1XS
ES4	NVzkdWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTRwNEewPVUh\|ryP	M1;URXNCVkeHUh?=
ES6	M4fjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXqSFVVUUN3ME20MlQ6PjV5IN88US=>	Mmq2V2FPT0WU
DMS-114	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTtTWM2OD12LkW0OlkyKM7:TR?=	NUHt[4syW0GQR1XS
ONS-76	NGrrfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vH[2lEPTB;ND61O\|k2KM7:TR?=	NHPvUG9USU6JRWK=
K-562	NWXrUHM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\RZ4RKSzVyPUSuO\|M5OTRizszN	NGr5VXhUSU6JRWK=
MHH-NB-11	NVq1UY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELnRY1KSzVyPUSuO\|U1PjFizszN	MY\TRW5ITVJ?
Calu-3	M1PLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjqTWM2OD12Lke4OVQ5KM7:TR?=	M1HkN3NCVkeHUh?=
HT55	NFzmOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor5TWM2OD12Lki0OVQ2KM7:TR?=	MYfTRW5ITVJ?
SK-N-FI	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTRwOEWwNFkh\|ryP	MlPzV2FPT0WU
ES1	NU\pdYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTRwOE[wOVch\|ryP	MoO2V2FPT0WU
SF126	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTRwOUOxPFQh\|ryP	M4LnWXNCVkeHUh?=
ES5	NUDoNHdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTVwMUK0Nlch\|ryP	M2\xdHNCVkeHUh?=
LoVo	M17hcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTVwMUW4O\|Eh\|ryP	MXXTRW5ITVJ?
SNU-387	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvXTWM2OD13LkOyN\|M6KM7:TR?=	MoDqV2FPT0WU
C8166	M3\S[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnLTWM2OD13LkO2N\|M6KM7:TR?=	NUnDXJliW0GQR1XS
LS-1034	M{m5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2m2XGlEPTB;NT60NlMxPyEQvF2=	NUXBVpBbW0GQR1XS
GR-ST	NVXLXnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi0T4FGUUN3ME21MlUzOjBzIN88US=>	M{HzOXNCVkeHUh?=
NCI-H1092	NHPNSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTVwN{K4OFMh\|ryP	Ml7xV2FPT0WU
647-V	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jBdmlEPTB;NT63OFcxPiEQvF2=	MnG3V2FPT0WU
EW-13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnH[VlKSzVyPUWuO\|Y3OjdizszN	MXHTRW5ITVJ?
KGN	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXRR4NKSzVyPU[uNFk6OjFizszN	NILmWGVUSU6JRWK=
D-423MG	NGe1WYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVztSXF7UUN3ME22MlQxOjh2IN88US=>	MWjTRW5ITVJ?
ECC10	NUfJZlVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvZPXJKSzVyPUeuNVAyODFizszN	MkXnV2FPT0WU
TE-5	NIHw[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvLTWM2OD15LkSxNlk5KM7:TR?=	M1WzTnNCVkeHUh?=
P12-ICHIKAWA	NGC4UI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XFOGlEPTB;Nz60OVUzOyEQvF2=	NGDIWIpUSU6JRWK=
NCI-H82	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGntdGJKSzVyPUeuOFU4ODFizszN	M{\TXHNCVkeHUh?=
NCI-H1993	NGHkb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTdwOEOwOlMh\|ryP	NGjs[VVUSU6JRWK=
RH-1	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTdwOEWyOFQh\|ryP	MnHIV2FPT0WU
SW948	NH3jXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\R[XpKSzVyPUeuPVYxPDlizszN	MorRV2FPT0WU
CAL-33	NUXuPZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf0[HNUUUN3ME23Mlk6QTN6IN88US=>	NYjjblNyW0GQR1XS
U-266	NWXIWG04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4C4WmlEPTB;OD6xOVc4PyEQvF2=	MYHTRW5ITVJ?
CAL-72	NYnDTVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7tTWM2OD16LkKwN\|Ih\|ryP	MoXOV2FPT0WU
SNU-423	NIfLZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTlwM{[2OlYh\|ryP	MULTRW5ITVJ?
KG-1	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTlwNUi0OVYh\|ryP	MYnTRW5ITVJ?
HCC1395	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XxcGlEPTB;OT65NlM2OiEQvF2=	NELDS4NUSU6JRWK=
BE-13	NHLvNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW4WXlyUUN3ME2xNE45QDl{IN88US=>	NITCTW9USU6JRWK=
MKN7	NU\UcJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DSe2lEPTB;MUCuPVc3PSEQvF2=	Ml:3V2FPT0WU
697	NEDtZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3n6NGlEPTB;MUGuNVQ4OiEQvF2=	MVnTRW5ITVJ?
LU-135	M3nYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4C1XmlEPTB;MUGuNlMxPyEQvF2=	M2Wxe3NCVkeHUh?=
ES7	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjDOJFIUUN3ME2xNU4{OzF\|IN88US=>	NUnVV2NLW0GQR1XS
SK-HEP-1	NELjXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XzXmlEPTB;MUGuO\|Y1PiEQvF2=	M3H4OHNCVkeHUh?=
BEN	NXzsNo5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPCTllKSzVyPUGxMlg2OSEQvF2=	NIrzPGNUSU6JRWK=
NCI-H1770	NYjydIhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTF{LkGyOkDPxE1?	MWjTRW5ITVJ?
SW13	NESxd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGi2WWVKSzVyPUGyMlE2PDFizszN	MXHTRW5ITVJ?
MZ1-PC	M3fPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHuxeohKSzVyPUGyMlU1PTJizszN	MoPsV2FPT0WU
Mo-T	NX3wTIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXuTWM2OD1zMj63OFIyKM7:TR?=	MXfTRW5ITVJ?
HLE	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTF{LkiyNVUh\|ryP	NU\wV5FyW0GQR1XS
RCC10RGB	NV;BN4Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzG[YtrUUN3ME2xN{43PzFizszN	NEX6SVNUSU6JRWK=
COLO-320-HSR	NWPWZ\|JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLrPG5KUUN3ME2xN{44OzhzIN88US=>	M1G5WnNCVkeHUh?=
BHT-101	NYjJOXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPMTWM2OD1zMz64N\|Q2KM7:TR?=	NXf4[lRsW0GQR1XS
OCUB-M	MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzlTWM2OD1zND6xOlAzKM7:TR?=	M{\EOXNCVkeHUh?=
MEG-01	NU\aOGozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPwbI9KSzVyPUG0MlM4ODhizszN	M17udXNCVkeHUh?=
RS4-11	NW\XSWdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTF2Lke0NkDPxE1?	MV3TRW5ITVJ?
MN-60	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK1SnRKUUN3ME2xOE44QDl2IN88US=>	Mke2V2FPT0WU
NCI-H1304	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDFbo5XUUN3ME2xOU4xPDJ3IN88US=>	MXrTRW5ITVJ?
Ramos-2G6-4C10	M{[4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPORWtKSzVyPUG1MlA2QDFizszN	MYXTRW5ITVJ?
NCI-H2342	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTPN2hWUUN3ME2xOU4zODR2IN88US=>	M2\T[3NCVkeHUh?=
LAN-6	M1LEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkflTWM2OD1zNT60OFE1KM7:TR?=	M4rUOHNCVkeHUh?=
JVM-2	NILSN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTF3LkW3OFgh\|ryP	MnvlV2FPT0WU
P30-OHK	NYf3RXMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfUTWM2OD1zNj6wOlE1KM7:TR?=	MmPjV2FPT0WU
C-33-A	M1fZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzJWWRXUUN3ME2xOk43OjF2IN88US=>	NWTId4g4W0GQR1XS
RPMI-8866	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPTRZBKSzVyPUG2Mlg1QTZizszN	NYrwfXlrW0GQR1XS
NCI-H630	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\vTWM2OD1zNj64OVM4KM7:TR?=	M4\xXHNCVkeHUh?=
KYSE-140	M{jYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETnfXZKSzVyPUG3MlIxOjhizszN	MWnTRW5ITVJ?
T84	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvEb3BtUUN3ME2xPE45Pjl3IN88US=>	MV7TRW5ITVJ?
KU-19-19	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVntXIJDUUN3ME2xPE46PjB6IN88US=>	NYjKV\|ZwW0GQR1XS
BALL-1	M{\nTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTF7LkOzPVkh\|ryP	MVvTRW5ITVJ?
Calu-6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTF7LkS5NkDPxE1?	NVHrUVFGW0GQR1XS
EGI-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jvb2lEPTB;MUmuOVk5KM7:TR?=	NULoN2plW0GQR1XS
MFH-ino	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PDZ2lEPTB;MUmuO\|Q2PCEQvF2=	MmC2V2FPT0WU
GB-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jNVGlEPTB;MkCuN\|U{PSEQvF2=	MVLTRW5ITVJ?
NCI-H1693	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJyLk[1NFUh\|ryP	M2PGenNCVkeHUh?=
SW1116	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLFd5VGUUN3ME2yNE46OzZ{IN88US=>	Ml;1V2FPT0WU
H-EMC-SS	MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXuTWM2OD1{Mj6wOFUh\|ryP	M4rETHNCVkeHUh?=
D-502MG	NUGyRnRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJ{LkiyOlEh\|ryP	NGnyc25USU6JRWK=
IA-LM	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfDeVZKSzVyPUKzMlI1QTNizszN	NGHK[HVUSU6JRWK=
SW1463	NXLSPIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL5RZZKSzVyPUKzMlc6KM7:TR?=	NHSwVJdUSU6JRWK=
JAR	NVvn[GtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojMTWM2OD1{ND6zNlk{KM7:TR?=	NGTK[VJUSU6JRWK=
HT	NW\1OppqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTJ2LkS3OVMh\|ryP	MYLTRW5ITVJ?
LCLC-103H	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml73TWM2OD1{ND64OFQ6KM7:TR?=	M3;zTnNCVkeHUh?=
SNU-449	NXLNNnFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHnXYhRUUN3ME2yOE45PzRzIN88US=>	MnTBV2FPT0WU
KE-37	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;4bnBKSzVyPUK1MlA6OjhizszN	NIT1R3BUSU6JRWK=
NCI-H1623	NIH0SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWqxeXBVUUN3ME2yO{4yOzB\|IN88US=>	NUf6dlBRW0GQR1XS
MOLT-13	NFLXNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTJ5LkO1NVYh\|ryP	M1L4UHNCVkeHUh?=
COLO-741	NFj6cWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPvNIVLUUN3ME2zNU4{OzN\|IN88US=>	M4HpTHNCVkeHUh?=
NB6	M2XXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTN{LkK4O\|Yh\|ryP	M{C1ZnNCVkeHUh?=
MOLT-16	NF;l[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;vTWM2OD1\|Mz6wNFU2KM7:TR?=	NGjCOnNUSU6JRWK=
IST-MES1	NUjKVZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Lw[GlEPTB;M{SuNFU1OSEQvF2=	M4DON3NCVkeHUh?=
A4-Fuk	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWewWY1mUUN3ME2zOU4xPjZizszN	M2\1UHNCVkeHUh?=
CAL-85-1	NGXITphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIiwUIVKSzVyPUO1MlI5OTdizszN	M{TBPHNCVkeHUh?=
CCRF-CEM	NVHzVW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zINmlEPTB;M{euNVU{PiEQvF2=	Mn7RV2FPT0WU
HAL-01	NILzbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jPXGlEPTB;M{iuOFg5QSEQvF2=	Ml3mV2FPT0WU
HEL	M4T1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTR\|LkO0NFkh\|ryP	MlfyV2FPT0WU
EW-1	NIe0b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTR\|LkS3Olgh\|ryP	NIjEfnhUSU6JRWK=
MDA-MB-231	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTR3LkGxPVkh\|ryP	NYe1VoxyW0GQR1XS
ABC-1	NEXNXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ezOGlEPTB;NE[uPFU{QCEQvF2=	NI\BeGdUSU6JRWK=
NCI-H446	M2PP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q3bGlEPTB;NEiuOVA2QCEQvF2=	MmjyV2FPT0WU
MHH-PREB-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7pUmZKSzVyPUS5MlYxODdizszN	M4e1TnNCVkeHUh?=
DOHH-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nnTmlEPTB;NEmuOlY2PiEQvF2=	M2rpW3NCVkeHUh?=
GCT	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP2[odKSzVyPUS5MlY6PzZizszN	M{fj[XNCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	+ 展開 Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
細胞試験： ^[1]	+ 展開細胞株： BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells 濃度： Dissolved in DMSO, final concentrations ~10 μM 反応時間： 5 days 実験の流れ： Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (参考用のみ)
動物試験：^[2]	+ 展開動物モデル： Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 製剤： Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle 投薬量： ~50 mg/kg 投与方法： Injection i.p. (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5%DMSO+corn oil 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Tanespimycin (17-AAG) SDFをダウンロードする

分子量	585.69
化学式	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
保管	3年 -20°C 粉
保管	2年 -80°C in solvent
別名	CP127374,NSC-330507, KOS 953

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00514371	Completed	Multiple Myeloma	Bristol-Myers Squibb	August 2007	Phase 2\|Phase 3
NCT00779428	Completed	Advanced Malignancies	Bristol-Myers Squibb	July 2006	Phase 2
NCT00354185	Terminated	Adult Nasal Type Extranodal NK/T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia/Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides/Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides/Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	May 2006	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
回答：
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90)シグナル伝達経路

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

相関HSP (e.g. HSP90)製品

PU-H71

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
FRAX597

FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

研究分野別

製品類型

Tanespimycin (17-AAG)

文献中Selleckの製品使用例(20)

カスタマーフィードバック(9)

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Tanespimycin (17-AAG) SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2018-11-16)

技術サポート

よくある質問（FAQ）

HSP (e.g. HSP90)シグナル伝達経路

HSP (e.g. HSP90) Inhibitors with Unique Features

相関HSP (e.g. HSP90)製品